scholarly journals Clinical usefulness of cancer antigen 125 biomarker for tuberculosis diagnosis: experience in Cali, Colombia

2021 ◽  
Vol 70 (3) ◽  
pp. e92921
Author(s):  
Carl Sebastian Leib ◽  
Luis Gabriel Parra-Lara ◽  
Robinson Pacheco ◽  
Jose Fernando García-Goez
Keyword(s):  
Positive Result ◽  
University Hospital ◽  
Ca 125 ◽  
Bivariate Analysis ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Negative Results ◽  
Tb Treatment ◽  
Significant Difference ◽  
Positive Results

Introduction: Diagnosing extra-pulmonary tuberculosis (EPTB) is a challenge for physicians. It has been suggested that cancer antigen 125 (CA-125), which is produced by mesothelial cells, may be an EPTB diagnostic biomarker. Objective: To describe serum CA-125 levels behavior in patients with TB treated in a referral university hospital located in Cali, Colombia. Materials and methods: A cross-sectional study was conducted in 99 TB patients with CA-125 measurements (U/mL) made before TB treatment was started, and treated at Fundación Valle del Lili between 2007 and 2016. Cases were classified as pulmonary TB (PTB) (n=33) or EPTB (n=66). A bivariate analysis was performed to compare the variables of interest (sociodemographic, clinical, and laboratory findings data) between EPTB and PTB groups, and to determine differences between patients with CA-125 positive results and those with negative results in relation to mortality. Results: Elevated CA-125 levels were reported in 55 patients (55.56%). Positive CA-125 results (>35 U/mL) were more frequent in the EPTB group (59.09% vs. 48.48%). In the EPTB group, positive results were found in tuberculous serositis cases (100% pericardial TB, 68.42% peritoneal TB and 66.66% pleural TB), and in 66.66% of miliary TB and TB of the spine cases, respectively. Also, 15 TB infection-related deaths were reported in the follow-up period (n=66), of which 13 had a CA-125 positive result, finding a significant difference with those with negative results (p=0.021), however 47.05% of the surviving patients also had a positive result. Conclusions: Most of tuberculous serositis, miliary and TB of the spine cases showed elevated CA-125 levels before starting TB treatment. CA-125 may prove to be useful for prognostic purposes in these patients.

An enzyme immunoassay procedure for cancer antigen 125 evaluated.

1988 ◽  
Vol 34 (12) ◽  
pp. 2513-2516 ◽  
Author(s):  
K W Ryder ◽  
T O Oei ◽  
M T Hull ◽  
M M Sample
Keyword(s):  
Positive Result ◽  
Ovarian Carcinoma ◽  
Receiver Operating Characteristic ◽  
Enzyme Immunoassay ◽  
Operating Characteristic ◽  
Ca 125 ◽  
Decision Threshold ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Receiver Operating Characteristic Curves

Abstract The performance of a new enzyme immunoassay (EIA) procedure (Abbott Labs.) for cancer antigen 125 (CA 125) met or exceeded the manufacturer's claims for all analytical variables examined. Overall correlation with results obtained with a radioimmunoassay (RIA) were good. However, near the decision thresholds typically chosen to define a positive result for ovarian carcinoma, EIA results were 10 to 20 arbitrary units/mL less than the RIA results. At specific decision thresholds, therefore, the sensitivities and specificities of the EIA and RIA procedure differed. Adjusting the decision thresholds gave a similar optimum efficiency for each procedure: EIA, 82.9% (decision threshold, 35 units/mL); RIA, 83.4% (decision threshold, 54 units/mL). Receiver-operating characteristic curves showed that the two procedures' ability to distinguish patients with active ovarian carcinoma from those with disease in remission was the same.

scholarly journals Cancer antigen 125 is associated with disease status in uterine carcinosarcoma

Rare Tumors ◽  
2019 ◽  
Vol 11 ◽  
pp. 203636131988415
Author(s):  
Malcolm Strachan Ross ◽  
Chelsea Kilpatrick Chandler ◽  
Koji Matsuo ◽  
John Austin Vargo ◽  
Esther Elishaev ◽  
...  
Keyword(s):  
Overall Survival ◽  
Uterine Cancer ◽  
Disease Status ◽  
Post Treatment ◽  
Uterine Carcinosarcoma ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Time Points ◽  
Potential Biomarker ◽  
Significant Difference

Uterine carcinosarcoma is a rare and aggressive tumor with poor outcomes. Cancer antigen 125 is routinely used to track the disease course of ovarian cancer and has been suggested as a biomarker in other aggressive forms of uterine cancer. We sought to characterize cancer antigen 125 as a potential biomarker of disease status in uterine carcinosarcoma. Clinical and pathological data were abstracted for patients who had surgical staging for a pathologically confirmed uterine carcinosarcoma at our institution from January 2000 to March 2014. Non-parametric tests were used to compare changes in cancer antigen 125. Elevated cancer antigen 125 (>35 U/mL) as a predictor of survival was assessed via Kaplan–Meier curves. Among the 153 patients identified, 66 patients had at least one paired measure of cancer antigen 125 drawn preoperatively, post-treatment, or at the time of disease recurrence, and 19 patients had cancer antigen–125 levels at all three time points. Analysis of the 51 patients with both preoperative and post-treatment values found a significant drop in cancer antigen 125 ( p < 0.001). Among the 30 patients who had end-of-treatment and recurrence levels, a significant increase was noted ( p = 0.001). There was no significant difference in cancer antigen–125 levels preoperatively compared to at recurrence among the 23 patients with levels at both time-points ( p = 0.99). Elevated preoperative cancer antigen 125 was not associated with overall survival ( p = 0.12); elevated post-treatment cancer antigen 125 was associated with a worse overall survival ( p < 0.001). Based on this dataset, there seems to be utility in trending a cancer antigen–125 level in patients with uterine carcinosarcoma. A cancer antigen–125 level could predict recurrence and provide prognostic information regarding survival.

Preoperative Measurement of Cancer Antigen 125 (CA 125) in the Differential Diagnosis of Ovarian Tumors

1989 ◽  
Vol 28 (4) ◽  
pp. 471-473 ◽  
Author(s):  
O. Mogensen ◽  
B. Mogensen ◽  
A. Jakobsen ◽  
A. Sell
Keyword(s):  
Differential Diagnosis ◽  
Ovarian Tumors ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen

Serum prolactin and CA 125 levels in uterine adenomyosis

2020 ◽  
Vol 12 (3-4) ◽  
pp. 165-169
Author(s):  
Ayçağ Yorganci ◽  
Nezaket Kadioğlu ◽  
Harika Gümgümcü ◽  
Şebnem Özyer ◽  
Yaprak Engin-Ustun
Keyword(s):  
Retrospective Chart Review ◽  
Thyroid Stimulating Hormone ◽  
Study Data ◽  
Ca 125 ◽  
Serum Prolactin ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Volume Group ◽  
Uterine Adenomyosis ◽  
Uterine Volume

Objective: It is suggested that prolactin has a role in the pathogenesis of uterine adenomyosis. Besides, it is also reported that elevated cancer antigen 125 levels are related with this benign disorder. The aim of the study was to investigate serum prolactin and cancer antigen 125 levels in patients with adenomyosis. Methods: In this retrospective chart review study, data of patients with clinically diagnosed and histopathologically proven adenomyosis in hysterectomy specimens were analyzed. Patients were divided into two groups according to the ultrasonographically calculated preoperative uterine volume: Group 1 (n = 62): uterine volume ⩽240 cm3 (⩽12 gestational weeks) and Group 2 (n = 42): uterine volume >240 cm3 (>12 gestational weeks). Age, obstetric history, body mass index, preoperative hemoglobin, thyroid stimulating hormone, prolactin and cancer antigen 125 levels, and ultrasonographic findings were recorded. Preoperative prolactin and cancer antigen 125 values were compared between the two groups. Results: A total of 104 patients were included in the study. No differences in the baseline characteristics were observed between the groups, except the number of pregnancies and miscarriages. Furthermore, no significant differences were observed in terms of serum prolactin and cancer antigen 125 levels between the groups. Conclusion: Serum prolactin and cancer antigen 125 levels were not associated with uterine volume in patients with uterine adenomyosis.

scholarly journals Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan

2020 ◽  
Vol 25 (6) ◽  
pp. 1163-1169
Author(s):  
Atsushi Ikeda ◽  
Takahiro Kojima ◽  
Koji Kawai ◽  
Shiro Hinotsu ◽  
Naoto Keino ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Positive Result ◽  
Recurrence Rates ◽  
Follow Up Study ◽  
Negative Results ◽  
Negative Findings ◽  
History Of ◽  
Muscle Invasive ◽  
Positive Results

Abstract Background A previous comparative study in Japan has demonstrated that the two consecutive UroVysion tests are useful tools to detect the presence of bladder cancer during follow-up after transurethral resection, but they also presented their high rates of false-positive results. Here, we aimed to evaluate the relationship between the UroVysion tests and subsequent intravesical recurrence. Methods In the previous study, patients without bladder cancer during the first analysis showed the same examination set repeated 3 months later as the second analysis. In this follow-up study, 326 patients showed negative findings confirmed on cystoscopy during the second UroVysion test. Recurrence-free survival was assessed using a median follow-up of 27 months. Results In the two consecutive UroVysion tests, 214 patients (65.6%) showed negative UroVysion results in both tests, whereas 91 presented a positive result on either tests and 21 patients presented positive results in both tests. During the follow-up, 40 patients (12.3%) had an intravesical recurrence with non-muscle-invasive bladder cancer. The recurrence rates in patients with negative results in both tests, those with one positive result in either tests, and those with positive results in both tests were 8.4%, 16.5%, and 33.3%, respectively. The multivariate analysis indicated that the history of bladder cancer and the consecutive UroVysion test pattern were independent risk factors for recurrence. Conclusions Our data confirmed the effectiveness of two consecutive UroVysion tests in predicting intravesical recurrence after TURBT. Further prospective studies would help determine an appropriate interval for cystoscopy follow-up.

Cancer antigen 125 (CA125) and the law of unintended consequences.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e18327-e18327
Author(s):  
Scheryll Paula Alken ◽  
Linda E. Coate ◽  
Bernie Woulfe ◽  
NIamh O'Leary ◽  
Ivana M Capin ◽  
...  
Keyword(s):  
Education Programme ◽  
Tumour Marker ◽  
Unintended Consequences ◽  
University Teaching ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Significant Difference ◽  
Serum Ca125 ◽  
The Cost ◽  
Finance Department

e18327 Background: CA125 is a serum tumour marker used to monitor patients with ovarian cancer (OvCa). Its usefulness as a screening tool remains unproven. There is no restriction in its use at our institution, a university teaching hospital. We sought to establish patterns of testing during one calendar year (2013), focussing on the economic costs of such unrestricted testing. Methods: A lookback of the CA125 reports issued by the Biochemistry Laboratory was undertaken. The CA125 requests were from physicians within the hospital & from the community. Individual requests for CA125 & those part of tumour marker panel were included & correlated with radiology & histopathology records to identify subsequent investigations (invxs) & diagnoses (dxs). Economic costings were provided by hospital finance department. For the purpose of this study we only included the costs of invxs triggered by out of range CA 125 test results. Results: In 2013, 7,132 CA125 measurements were performed. 871 repeat tests, 40 tests performed on men & 16 tests with inadequate patient identifiers were excluded. Of the remaining 6,205 patient tests; median age was 53yrs (range 13 – 96yrs); median CA125 was 5.5 IU/L (range 0.1 – 22452 IU/L). Out of range tests (>35 IU/L) led to 619 ultrasound scans, 339 CT scans. In total, 20 new cases of OvCa were dx. The crude cost per new dx was €11,459.80. Median time to diagnosis was 4 days (range -2 – 251), median CA125 at dx was 271 (range 8.1 - 9444). Median age at dx was 62 (range 40 – 87). 65% of dx were made during inpatient stays;10% by family physicians;25% by gynaecologists. There was a statistically significant difference in median CA125 in patients diagnosed with OvCa, compared to those who were not dx with a malignant condition (p<0.0001); this was not true of age at dx (p=0.27). Conclusions: This study underlines the lack of efficacy in unrestricted serum CA125 testing & that such testing creates a significant economic burden on hospitals, far in excess of the cost of the CA125 test alone. We plan to implement guidelines in our institution & will reassess this issue following an education programme with local clinicians. [Table: see text]

scholarly journals Immunohistochemical Study of CA 125 in Surface Epithelial Tumors of Ovary in Correlation with Serum Levels

2020 ◽  
Vol 7 (7) ◽  
pp. A355-360
Author(s):  
Karishma Pillarisetty ◽  
Savithri Ravindra
Keyword(s):  
Ovarian Cancer ◽  
Ovarian Neoplasms ◽  
Serum Levels ◽  
Tissue Expression ◽  
Epithelial Differentiation ◽  
Ca 125 ◽  
Cancer Antigen 125 ◽  
Cancer Antigen ◽  
Epithelial Tumors ◽  
Wide Range

Background: Ovarian carcinoma is the 4th leading cancer among women in India. Primary ovarian neoplasms exhibit a wide range of histopathological patterns and tumors with epithelial differentiation are most frequent. Among malignant tumors, most common histological type is serous adenocarcinoma whose diagnosis is established in advanced stages of disease in approximately 75% of patients. The most widely used tumor marker in ovarian cancer, often considered “gold standard” is Cancer Antigen125. Cancer Antigen 125 is a high molecular weight glycoprotein which is raised in approximately 90% of patients with advanced epithelial ovarian cancer.   Methods: A 2 year prospective study included 81 cases of ovarian neoplasms with surface epithelial differentiation.  The specimens were fixed in 10% formalin, routinely processed. Sections of 4-5 microns thickness were obtained from the paraffin block and stained with Hematoxylin & Eosin. The tumors were categorised according to WHO classification.  Immunohistochemical analysis of Cancer Antigen 125 was done in all malignant & borderline tumors.   Result: A total of 81 cases were studied. There were 15 cases with elevated serum Cancer Antigen 125 levels. Of these 8 showed positive tissue expression. The sensitivity of serum Cancer Antigen 125 was 68.75% & its specificity was 93.8%.   Conclusion: Serum Cancer Antigen 125 is elevated in ovarian tumors especially in malignant surface epithelial tumors & more commonly in serous cystadenocarcinoma. There was a good correlation between serum levels & tissue expression of Cancer Antigen 125.

scholarly journals A surge of p-values between 0.041 and 0.049 in recent decades (but negative results are increasing rapidly too)

2014 ◽  
Author(s):  
Joost de Winter ◽  
Dimitra Dodou
Keyword(s):  
Social Sciences ◽  
Quantitative Research ◽  
The United States ◽  
Physical Sciences ◽  
Questionable Research Practices ◽  
Reporting Practices ◽  
Negative Results ◽  
Significance Threshold ◽  
Significant Difference ◽  
Positive Results

It is known that statistically significant (positive) results are more likely to be published than non-significant (negative) results. However, it has been unclear whether any increasing prevalence of positive results is stronger in the “softer” disciplines (social sciences) than in the “harder” disciplines (physical sciences), and whether the prevalence of negative results is decreasing over time. Using Scopus, we searched the abstracts of papers published between 1990 and 2013, and measured longitudinal trends of multiple expressions of positive versus negative results, including p-values between 0.041 and 0.049 versus p-values between 0.051 and 0.059, textual reporting of “significant difference” versus “no significant difference”, and the reporting of p < 0.05 versus p > 0.05. We found no support for a “hierarchy of sciences” with physical sciences at the top and social sciences at the bottom. However, we found large differences in reporting practices between disciplines, with p-values between 0.041 and 0.049 over 1990–2013 being 65.7 times more prevalent in the biological sciences than in the physical sciences. p-values near the significance threshold of 0.05 on either side have both increased but with those p-values between 0.041 and 0.049 having increased to a greater extent (2013-to-1990 ratio of the percentage of papers = 10.3) than those between 0.051 and 0.059 (ratio = 3.6). Contradictorily, p < 0.05 has increased more slowly than p > 0.05 (ratios = 1.4 and 4.8, respectively), while the use of “significant difference” has shown only a modest increase compared to “no significant difference” (ratios = 1.5 and 1.1, respectively). We also compared reporting of significance in the United States, Asia, and Europe and found that the results are too inconsistent to draw conclusions on cross-cultural differences in significance reporting. We argue that the observed longitudinal trends are caused by negative factors, such as an increase of questionable research practices, but also by positive factors, such as an increase of quantitative research and structured reporting.

Cancer Antigen 125 Levels are Significantly Associated With Prognostic Parameters in Uterine Papillary Serous Carcinoma

2018 ◽  
Vol 28 (7) ◽  
pp. 1311-1317 ◽  
Author(s):  
Meirav Schmidt ◽  
Yakir Segev ◽  
Rotem Sadeh ◽  
Erica Suzan ◽  
Ido Feferkorn ◽  
...  
Keyword(s):  
Lymph Node ◽  
Serous Carcinoma ◽  
Ca 125 ◽  
Prognostic Parameters ◽  
Cancer Antigen 125 ◽  
Optimal Cutoff ◽  
Positive Cytology ◽  
Cancer Antigen ◽  
Uterine Papillary Serous Carcinoma ◽  
Papillary Serous Carcinoma

ObjectivesUterine papillary serous carcinoma (UPSC) is a highly aggressive subtype of endometrial carcinoma. Histopathologically, it resembles the pattern of serous papillary carcinoma of the ovary. Cancer antigen 125 (CA-125) is the most widely used biomarker in epithelial ovarian carcinoma. Its use in UPSC evaluation has yet to be determined. The purpose of this study was to investigate the significance of preoperative serum CA-125 as a prognostic factor in patients with UPSC.MethodsThe study cohort included all women with UPSC operated in our institution between January 2002 and June 2016. All patients underwent complete surgical staging. Preoperative CA-125 was reviewed and correlated with clinical and pathological parameters.ResultsSixty-one women met the study criteria. Median preoperative CA-125 was found to be significantly associated with disease stage. Patients with disease stages I to IV had median preoperative CA-125 levels of 12.15, 19.6, 22.6, and 177.5 U/mL (P < 0.0001) respectively. Levels of CA-125 were significantly associated with positive cytology (P < 0.0001), omental disease (P < 0.0001), pelvic or para-aortic lymph node metastasis (P < 0.0001), and adnexal involvement (P < 0.0001). The optimal cutoff that provided the best sensitivity and specificity for omental and parametrial involvement as well as positive cytology was 57.5 U/mL. For adnexal and lymph node involvement, the optimal cutoff value was 41.8 U/mL.ConclusionsIn patients with UPSC, preoperative CA-125 level correlates with known prognostic parameters of endometrial carcinoma and is associated with extrauterine involvement. These data should stimulate the need for further evaluation of the role of CA-125 in predicting recurrence and survival in UPSC.

Sign in / Sign up

Export Citation Format

Share Document